You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,771,966


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,771,966
Title:Polypeptide cleavage process
Abstract: A palladatepalladium-promoted hydrolytic polypeptide cleavage process which selectively cleaves the polypeptide at a Cys-His cleavage site comprising solubilizing the polypeptide in a reaction mixture comprised of a palladatepalladium promoter dissolved in a high-concentration acidic organic acid solvent.
Inventor(s): Seo; Jin Seog (Mississauga, CA), Strydom; Daniel (Lincoln, NE), Holmquist; Barton (Eagle, NE)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Application Number:10/997,762
Patent Claims:1. A process for producing a polypeptide comprising: (a) expressing a recombinant chimeric protein from an expression vector in a host cell, wherein the chimeric protein comprises a leader sequence joined by a Cys-His cleavage site to the N-terminus of the polypeptide and recovering the chimeric protein from the host cell in the form of an inclusion body and wherein the chimeric protein comprises a vestigal sequence of the amino acids 15-41 of SEQ ID NO:15 to induce formation of the inclusion body; (b) cleaving the polypeptide from the chimeric protein by solubilizing the inclusion body recovered in step (a) in a reaction mixture comprised of a palladium promoter dissolved in a high-concentration organic solvent selected from the group consisting of acetic acid, citric acid, dicarboxylic acid, lactic acid, maleic acid, malonic acid, propionic acid, pyruvic acid, tartaric acid, and tricarballylic acid, wherein the concentration of the organic solvent in the reaction mixture is between 1 to 22 molar; and (c) recovering the cleaved polypeptide from the reaction mixture of step (b) by ultrafiltration, filtration or ion-exchange chromatography.

2. The process of claim 1, wherein the reaction mixture has a molar ratio of palladium promoter to inclusion body from about 2:1 to about 20:1.

3. The process of claim 1, wherein the reaction mixture is maintained at a temperature of about 50.degree. C. to about 70.degree. C.

4. The process of claim 1, wherein step (b) proceeds for 1 to 6 hours.

5. The process of claim 1, wherein the cleavage site includes a linker, which is adjacent to Cys.

6. The process of claim 5, wherein the linker is selected from the group consisting of DDDD (SEQ ID NO:10), DDDK (SEQ ID NO:11), DTRL (SEQ ID NO:12), and GGPR (SEQ ID NO:13).

7. The process of claim 1, wherein the organic solvent is combined with one or more palladium complexes with ligands selected from the group consisting of ethylenediamine; propylenediamine; 2-aminomethyl pyridine; 2(2-aminoethyl) pyridine; 2(2-methylaminoethyl)pyridine; 2,2'-bypyridyl; 1,10-phenanthroline: 3-hydroxy-2(dimethylaminomethyl)pyridine; 3-hydroxy-1,5-dithiacyclooctane; 3,6-dithiaoctane-1,8-diol; 1,2-diphenylphosphineethane; triphenylphosphine; diphenylphosphineferrocene; and diethylenetriamine.

8. The process of claim 2, wherein the palladium promoter is a Palladium(II) complex selected from the group consisting of Na.sub.2PdCl.sub.4; cis-[Pd(en)Cl.sub.2]; cis-[Pd(bp)Cl.sub.2]; cis-[Pd(phen)Cl.sub.2]; cis-[Pd(pn)Cl.sub.2]; cis-[Pd(pic)Cl.sub.2]; cis-[Pd(dtco-OH)Cl.sub.2cis-[Pd(en)(OH.sub.2).sub.2].sup.2+, cis-[Pd(pn)(OH.sub.2).sub.2].sup.2+, cis-[Pd(pic)(OH.sub.2).sub.2].sup.2+, cis-[Pd(bp)(OH.sub.2).sub.2].sup.2+; cis-[Pd(phen)(OH.sub.2).sub.2].sup.2+; cis-[Pd(dtco-OH)(OH.sub.2).sub.2].sup.2+; and [Pd(OH.sub.2).sub.3(OH)](NO.sub.3).

9. The process of claim 2, wherein the polypeptide is a recombinant growth hormone releasing factor, the host cell is Escherichia coli and the chimeric protein is T7tag-Vg-D4K-CH-GRF (1-44)-CH (SEQ ID NO:1).

10. The process of claim 2, wherein the polypeptide is rPTH, the host cell is Escherichia coli and the chimeric protein is T7tag-Vg-G.sub.5PR-CH-PTH(1-34) (SEQ ID NO:3).

11. The process of claim 2, wherein the polypeptide is rPTH, the host cell is Escherichia coli and the chimeric protein is T7tag-Vg-D4K-CH-PTH(1-84) (SEQ ID NO:4).

12. The process of claim 1, wherein the organic solvent is combined with an inorganic acid selected from the group consisting of HCl, H.sub.3PO.sub.4, H.sub.2SO.sub.4, HClO.sub.4, or HClO.sub.4.

13. The process of claim 1, wherein the organic solvent is malonic acid.

14. The process of claim 13, wherein the organic solvent is 5 M malonic acid or 6 M malonic acid and the palladium promoter is tetrachloropalladate.

15. The process of claim 13, wherein the reaction mixture has a molar ratio of tetrachloropalladate to the chimeric protein around 10:1.

16. The process of claim 2, wherein the polypeptide is glucagon-like peptide-1, glucagon-like peptide-2, growth hormone releasing hormone, parathyroid hormone, parathyroid hormone releasing hormone, adrenocorticotropic hormone, enkephalins, endorphins, exendins, amylins, opioid peptides, gaegurin 5, gaegurin 6, brevinin 1, ranatuerin 1 through 9, an esculetin, glucose-dependent insulinotropic polypeptide, glucagon, motilin, a thymopoietin, a thymosin, ubiquitin, serum thymic factor, thymic humoral factor, neurotensin or tuftsin.

17. The process of claim 2, wherein the polypeptide is gastrin, calcitonin, luteinizing-hormone-releasing hormone, pancreatic polypeptide, endothelin, corticotrophin releasing factor, neuropeptide Y, atrial naturetic peptide, amylin, galanin, somatostatins, vasoactive intestinal peptide or insulin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.